Learning Goal: I’m working on a writing discussion question and need an explanat

Learning Goal: I’m working on a writing discussion question and need an explanation to help me learn.What interventions could be utilized in order to overcome these challenges? Response to Michaeline Youngkendeh Leukemia is a type of blood cancer caused by a breakdown in normal cellular regulation, resulting in the uncontrolled production of immature WBCs in the bone marrow. As a result, the bone marrow becomes overcrowded with immature, nonfunctional cells, and the production of other normal blood cell types decreases significantly. Acute leukemia has a sudden onset, whereas chronic leukemia has a slow onset and symptoms that last for years. Cancer most commonly occurs in stem cells or early precursor leukocyte cells in leukemia, causing excessive growth of one type of immature leukocyte. Excessive bone marrow production halts average bone marrow production, resulting in anemia, thrombocytopenia, and leukopenia. Induction chemotherapy is a high-dose chemotherapy regimen that lasts about a week. The goal is to clear the blood of leukemia cells and return the bone marrow blast count to normal. Imatinib mesylate is the first-line treatment for chronic myelogenous leukemia (CML). This oral medication has shown to be effective in inducing remission in the early stages of CML. Hematopoietic stem cell transplantation is a standard treatment option for patients with acute leukemia who have a closely matched donor and are in remission after induction therapy. Immune changes increase the risk of infection in leukemia patients. Even if the WBC count is average or high, these cells are immature and cannot protect the patient from infection. Acute leukemia severely limits platelet production in the bone marrow, resulting in thrombocytopenia. In response to minor trauma, the patient is at high risk for poor clotting and excessive bleeding. Induction therapy or high-dose chemotherapy for transplantation can also cause thrombocytopenia. Response to Zaina Sandra Asiimwe Hemophilia is usually an inherited bleeding disorder where the blood can not clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. The severity of hemophilia that a person has is determined by the number of factors in the blood. People with hemophilia have low factor VIII (8) or factor IX (9). Hemophilia A results from a deficiency of factor VIII and is the most common type of hemophilia. Hemophilia B results from a defect in factor IX and is less common. The lower the amount of the factor, the more likely it is that bleeding will occur, which can lead to serious health problems (CDC, 2020) Hemophilia is caused by a mutation or change in one of the genes that provide instructions for making the clotting factor proteins needed to form a blood clot. Males can have hemophilia if they inherit an affected X chromosome that has a mutation in factor VIII or factor IX gene. Females can also have it but rarely only in cases where both X chromosomes are affected, or one is affected, and the other is missing or inactive. In these females, bleeding symptoms may be like males with hemophilia. Hemophilia can result in bleeding within joints that can lead to chronic joint disease and pain. Percolating in the head and sometimes in the brain. This can cause long-term problems, such as seizures and paralysis, or even death can occur if the bleeding cannot be stopped or if it occurs in a vital organ such as the brain. The best way to treat hemophilia is to replace the missing blood clotting factor so that the blood can clot properly. This is done by infusing (administering through a vein) commercially prepared factor concentrates. The two main types of clotting factor concentrate are available: Plasma-derived Factor Concentrates and Recombinant Factor Concentrates. Other Treatment Products include Hemlibra®, which works by replacing factor VIII (8) function, rather than directly replacing the missing clotting factor VIII, DDAVP®, or Stimate® (Desmopressin Acetate), Cryoprecipitate and others. The challenges that could arise in carrying out these strategies and providing care may be that even slight trauma can result in a hematoma, potentially impinge on organs, nerves, and vessels. These hematomas can grow quite large and escape clinical detection until neurologic complications related to nerve compression appear. Also, there is a potential risk of developing inhibitors, especially among African American and Latino patients who are more likely to develop an inhibitor than Caucasian patients. More challenges include Comorbid Conditions, blood-borne infection, Obesity, renal disease, cardiovascular disease, and it has narrowed the life expectancy gap between patients with hemophilia and the general population (Bauer, 2015)
Requirements: short

Leave a comment

Your email address will not be published. Required fields are marked *